IDEXX Laboratories Provides U.S. Companion Animal Market Trends Update

WESTBROOK, Maine, May 26, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today provided an update on U.S. Companion Animal Market Trends through Friday, May 22^nd.

We are monitoring the impact of the COVID-19 pandemic on U.S. companion animal practice visit trends, including the effect of stay-at-home and social distancing policies to prevent the spread of COVID-19, as well as the related prioritization of sick and emergency testing at veterinary clinics. With an additional four weeks of activity since our last update, we continue to see meaningful improvement in U.S. clinical visit trends across major regions, with overall U.S. clinical visits, non-wellness visits and wellness visits surpassing prior year levels in the most recent week ended May 22^nd.

The U.S. Companion Animal Market Trends Snapshot is available on the IDEXX website, www.idexx.com/investors

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a member of the S&P 500^® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, tests for the quality and safety of water and milk, and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectation or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).

Contact:

Media Relations
MSL Group
1-781-684-0770
[email protected]

Investor Relations
John Ravis
1-207-556-8155
[email protected]

SOURCE IDEXX Laboratories, Inc.